02.10.14
Irvine, Calif.-based Endologix Inc. has launched the Vela proximal endograft system in the United States. The system earned pre market approval from the U.S. Food and Drug Administration (FDA) in June last year. It is specifically designed for the treatment of proximal aortic neck anatomies during an endovascular aneurysm repair (EVAR) procedure using the Endologix AFX endovascular AAA (abdominal aortic aneurysm) system. The proximal neck is the portion of the aorta that is above the aneurysm and below the renal arteries.
“Vela is a next generation proximal endograft, designed based on our dedication to innovation leadership in AAA and feedback we collected from leading physicians,” said John McDermott, chairman and CEO of Endologix. “Vela’s new delivery system and unique circumferential graft line marker provide physicians with enhanced visibility and greater control over the implant procedure. We believe these enhancements lead to better precision and predictability of graft placement when coupled with our proprietary ActiveSeal technology. These features make Vela an attractive clinical solution for endovascular repair in a broad range of aortic neck anatomies.”
One of the first Vela procedures in the United States was performed by Julio Rodriguez, M.D. FACS, a Vascular Surgeon at the Arizona Heart Institute.
Rodriguez commented, “The Vela delivery system is very intuitive and the endograft has excellent visibility. Our early experience has been very positive and we are planning to use the Vela proximal endograft in a live EVAR procedure on February 12, 2014 at the iCON meeting in Phoenix, Arizona.”
The International Congress on Endovascular Interventions (iCON) is an annual medical meeting for vascular specialists from around the world.
Endologix makes minimally invasive treatments for aortic disorders.
“Vela is a next generation proximal endograft, designed based on our dedication to innovation leadership in AAA and feedback we collected from leading physicians,” said John McDermott, chairman and CEO of Endologix. “Vela’s new delivery system and unique circumferential graft line marker provide physicians with enhanced visibility and greater control over the implant procedure. We believe these enhancements lead to better precision and predictability of graft placement when coupled with our proprietary ActiveSeal technology. These features make Vela an attractive clinical solution for endovascular repair in a broad range of aortic neck anatomies.”
One of the first Vela procedures in the United States was performed by Julio Rodriguez, M.D. FACS, a Vascular Surgeon at the Arizona Heart Institute.
Rodriguez commented, “The Vela delivery system is very intuitive and the endograft has excellent visibility. Our early experience has been very positive and we are planning to use the Vela proximal endograft in a live EVAR procedure on February 12, 2014 at the iCON meeting in Phoenix, Arizona.”
The International Congress on Endovascular Interventions (iCON) is an annual medical meeting for vascular specialists from around the world.
Endologix makes minimally invasive treatments for aortic disorders.